Sally Turla

509 citations
8 papers · 399 indexed · h-index 7
Topics
Virus-based gene therapy research (3 papers)Cancer Research and Treatments (3 papers)Cancer-related Molecular Pathways (3 papers)
Partner nations
United States

In The Last Decade

Sally Turla

8 papers receiving 385 citations

Peers

Sally Turla
Comparison fields: 5 of 56
  • Molecular Biology 285
  • Oncology 129
  • Pulmonary and Respiratory Medicine 76
  • Cancer Research 74
  • Genetics 71
Replace S. Oriana with:
S. Oriana Italy
Christine Challen United Kingdom
Pnina Yaron United States
You Lu China
Jason Lukas United States
Francesc Madriles Spain
J Y J Wang United States
Christopher Kimberley United Kingdom
Sebastien M. Joruiz United States
Nilesh Gardi India
Sally Turla relative to S. Oriana Italy S. Oriana's profile →
Citations per field
00.5×10×14×
S. Oriana · 1×
Citations per year

Countries citing papers authored by Sally Turla

Since Specialization
Citations

This map shows the geographic impact of Sally Turla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sally Turla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sally Turla more than expected).

Fields of papers citing papers by Sally Turla

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sally Turla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sally Turla. The network helps show where Sally Turla may publish in the future.

Co-authorship network of co-authors of Sally Turla

This figure shows the co-authorship network connecting the top 25 collaborators of Sally Turla. A scholar is included among the top collaborators of Sally Turla based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sally Turla. Sally Turla is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
#WorkIndexed citations
1 99
2 96
3 45
4 4
5
Inhibition of the Jun kinase pathway blocks DNA repair, enhances p53-mediated apoptosis and promotes gene amplification.
27
6 39
7 9
8 80

About Sally Turla

Sally Turla is a scholar working on Biotechnology, Cancer Research and Oncology, having authored 8 papers that have together received 399 indexed citations. Recurring topics across this work include Virus-based gene therapy research (3 papers), Cancer Research and Treatments (3 papers) and Cancer-related Molecular Pathways (3 papers). The work is most often cited by research in Biotechnology (54 citations), Cancer Research (74 citations) and Oncology (129 citations). Sally Turla has collaborated with scholars based in United States. Frequent co-authors include Ruth A. Gjerset, Kimberly D. Siegmund, Peter W. Laird, Janice S. Galler, Ite A. Laird‐Offringa, Michael N. Koss, Jeffrey A. Hagen, Dan Mercola, Jeffrey A. Tsou and Robert E. Sobol. Their work appears in journals such as Journal of neurosurgery, Molecular Cancer and The Journal Of Hand Surgery.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026